Filgrastim Research Paper
Drug Card for Filgrastim
Brand name: Neupogen
Classification: Therapeutic: Colony-stimulating factors
Indications: Prevention of febrile neutropenia and associated infection in patients who have recevied bone marrow-depressing antineoplastics.
Action: Glycoprotein that binds to and stimulates immature neutrophils to divide and differentiate
Pharmacokinetics: Well absorbed with subQ. Distribution, and metabolism and excretion are unknown. Half life is 3.5 hours
Time: Route is IV or SubQ. Onset is unknown, Peak is unknown, duration 4 days
Contraindiacted: hypersensitivity to filgrastim or E-Coli-derived proteins
Side effects: excessive leukocytosis, pain, redness at injection site, medullary bone pain
Drug-Drug interactions: Simulataneous …show more content…
After myelosuppressive Chemo: 5mcg/kg/day as single dose for up to 2 weeks. Can be increased by 5mcg/kg during each cycle of chemo. After bone marrow transplant: 10 mcg/ky/day as a 4 or 24 hour infusion or as a continuous subQ infusion.
Implications: Monitor vitals before and during, assess bone pain
Lab considerations: Obtain a CBC with diff and platelet count before chemo and after chemo, and twice weekly during therapy. Monitor ANC. A rise may be seen 1-2 days after initiation of therapy, but therapy should not be discontiuned until ANC is greater than 10,000/mm. May cause decreased platelets, and transient increases in uric acid, LDH, and alkaline phosphatase concentrations.
Nsg Diagnosis: Risk for pain, Risk for infection, Risk for …show more content…
By doing this, the cancer cell does not have the substances needed for formation of DNA or cause formation of abnormal DNA. These types of drugs will only work when the cell is in the S phase of the cell cycle (Abramms, Lammon, & Pennington, 2009). These drugs are most effective in rapidly growing tumors, and individual drugs vary in effectiveness with different kinds of cancer. Most of these drugs are given orally or IV. These drugs can cause bone marrow depression, mucositis, and GI ulceration, and hair loss. Teaching patients what to monitor for, and ways to decrease chances of such things are important. Monitoring blood pressure is necessary too as some of the drugs can cause increased blood
Brand name: Neupogen
Classification: Therapeutic: Colony-stimulating factors
Indications: Prevention of febrile neutropenia and associated infection in patients who have recevied bone marrow-depressing antineoplastics.
Action: Glycoprotein that binds to and stimulates immature neutrophils to divide and differentiate
Pharmacokinetics: Well absorbed with subQ. Distribution, and metabolism and excretion are unknown. Half life is 3.5 hours
Time: Route is IV or SubQ. Onset is unknown, Peak is unknown, duration 4 days
Contraindiacted: hypersensitivity to filgrastim or E-Coli-derived proteins
Side effects: excessive leukocytosis, pain, redness at injection site, medullary bone pain
Drug-Drug interactions: Simulataneous …show more content…
After myelosuppressive Chemo: 5mcg/kg/day as single dose for up to 2 weeks. Can be increased by 5mcg/kg during each cycle of chemo. After bone marrow transplant: 10 mcg/ky/day as a 4 or 24 hour infusion or as a continuous subQ infusion.
Implications: Monitor vitals before and during, assess bone pain
Lab considerations: Obtain a CBC with diff and platelet count before chemo and after chemo, and twice weekly during therapy. Monitor ANC. A rise may be seen 1-2 days after initiation of therapy, but therapy should not be discontiuned until ANC is greater than 10,000/mm. May cause decreased platelets, and transient increases in uric acid, LDH, and alkaline phosphatase concentrations.
Nsg Diagnosis: Risk for pain, Risk for infection, Risk for …show more content…
By doing this, the cancer cell does not have the substances needed for formation of DNA or cause formation of abnormal DNA. These types of drugs will only work when the cell is in the S phase of the cell cycle (Abramms, Lammon, & Pennington, 2009). These drugs are most effective in rapidly growing tumors, and individual drugs vary in effectiveness with different kinds of cancer. Most of these drugs are given orally or IV. These drugs can cause bone marrow depression, mucositis, and GI ulceration, and hair loss. Teaching patients what to monitor for, and ways to decrease chances of such things are important. Monitoring blood pressure is necessary too as some of the drugs can cause increased blood